Business Context and Reporting Period
Company: The Estée Lauder Companies Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2024 (Fiscal 2025 Q2).
Business Overview: A global manufacturer and marketer of prestige beauty products including skin care, makeup, fragrance, and hair care, distributed in approximately 150 countries.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Dec 31, 2024 | 6 Months Ended Dec 31, 2024 |
|---|---|---|
| Net Sales | $4,004 | $7,365 |
| Gross Profit | $3,047 | $5,480 |
| Gross Margin | 76.1% | 74.4% |
| Operating Income (Loss) | $(580) | $(701) |
| Net Earnings (Loss) | $(590) | $(746) |
| Diluted EPS | $(1.64) | $(2.07) |
| Cash and Cash Equivalents | $2,586 | $2,586 (Ending Balance) |
| Total Debt | $7,280 | $7,280 (Ending Balance) |
| Operating Cash Flow | N/A | $387 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6% year-over-year for both the three and six-month periods, driven primarily by volume declines of 11% and 9% respectively. Pricing actions provided a 4% offset.
- Significant Impairments: The company recorded a non-cash impairment charge of $861 million related to goodwill and other intangible assets. This included a $773 million charge for the TOM FORD trademark and $75 million for Too Faced, triggered by lower-than-expected growth in key regions (China, Asia travel retail) and increased weighted average cost of capital.
- Restructuring Charges: Restructuring and other charges totaled $181 million for the quarter and $278 million for the six months, associated with the expanded "Profit Recovery and Growth Plan" (PRGP).
- Legal Settlements: A $159 million charge was recorded in the first quarter (included in six-month data) for talcum litigation settlement agreements covering current and future claims.
- Profitability: Operating margin turned negative (-14.5% for the quarter) compared to 13.4% in the prior year, primarily due to the impairment charges and sales decline, despite an improvement in gross margin.
Guidance, Outlook, and Risks
- Restructuring Expansion: On February 3, 2025, the company expanded the PRGP. The total estimated charges for the program are now $1.2 billion to $1.6 billion, with a target net reduction of 5,800 to 7,000 positions (9-11% of the workforce). The company expects annual gross benefits of $800 million to $1 billion upon completion.
- Market Outlook: Management expects continued volatility due to subdued consumer sentiment in China and Korea, challenges in North America retail sales, and geopolitical risks including potential tariffs.
- Legal Contingencies: The company faces ongoing litigation regarding cosmetic talcum powder. While a settlement process was established for certain firms, risks remain regarding other plaintiff firms and unasserted claims.
- Non-GAAP Adjustments: Adjusted operating income (excluding impairments, restructuring, and litigation charges) decreased 20% for the quarter and 12% for the six months, indicating underlying operational pressure beyond one-time charges.
Investor Verification Checklist
- Impairment Assumptions: Verify the weighted average cost of capital (11.5% for TOM FORD, 14% for Too Faced) and revenue growth assumptions used in the fair value calculations.
- China Exposure: Assess the specific impact of the "subdued sentiment" in mainland China and the exit of Dr.Jart+ from the Korean travel retail channel on future revenue guidance.
- Restructuring Execution: Monitor the timeline and cost realization of the expanded PRGP, specifically the outsourcing of services and supply chain optimization.
- Talcum Litigation: Review the scope of the settlement agreements and the potential exposure from law firms not included in the current settlement.
- Liquidity Position: Confirm the sufficiency of cash flows to fund the expanded restructuring program ($1.2B-$1.6B total charges) alongside dividend payments and debt maturities.